Gilead stops leukaemia drug trial early PharmaTimes The safety profile of the drug was also found to be "acceptable and consistent with prior experience" when combing it with rituximab in previously treated CLL. Norbert Bischofberger, Gilead's R&D chief, said the firm is pleased that idelalisib has ... |
